Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

BACKGROUND. The CHER-LOB randomized phase II study showed that the combination of lapatinib and trastuzumab plus chemotherapy increases the pathologic complete remission (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. A biomarker program was prospectively planned to ident...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncologist
Prif Awduron: Guarneri, Valentina, Dieci, Maria Vittoria, Frassoldati, Antonio, Maiorana, Antonino, Ficarra, Guido, Bettelli, Stefania, Tagliafico, Enrico, Bicciato, Silvio, Generali, Daniele Giulio, Cagossi, Katia, Bisagni, Giancarlo, Sarti, Samanta, Musolino, Antonino, Ellis, Catherine, Crescenzo, Rocco, Conte, PierFranco
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AlphaMed Press 2015
Pynciau:
Breast Cancer
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4571802/
https://ncbi.nlm.nih.gov/pubmed/26245675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0138
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg